Cost-efficiency analysis of conversion to biosimilar filgrastim for supportive cancer care and resultant expanded access analysis to supportive care and early-stage HER2+ breast cancer treatment in Saudi Arabia: simulation study.
Consuela Cheriece YousefMansoor Ahmed KhanHind Saleh AlmodaimeghMajed A AlshamraniMeteb Al-FoheidiHana AlabdulkarimAhmed Hamdan Al-JedaiAnjum NaeemIvo AbrahamPublished in: Journal of medical economics (2023)
This simulation study demonstrated significant potential cost-savings from biosimilar conversion. These savings provide budget-neutral increased access to supportive and therapeutic cancer care.